Managed Care Review Board®: New Guidelines, Treatment Options, and Benefit Management Strategies for Eosinophilic Esophagitis
Learn About:
| Expert Faculty Presenters | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
Target Audience
The primary target audience for this initiative consists of medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations. Other managed care professionals include nurses, case managers, policy administrators, utilization managers, C-suite executives, and IT professionals.
Statement of Need/Program Overview
Eosinophilic esophagitis (EoE) is difficult to diagnosis and treat, and as a result is associated with a high disease burden. Managed care and payer professionals are well positioned to design and implement policies that have a considerable influence on EoE patient access to appropriate care. This educational activity is designed to increase participants’ knowledge and competence regarding the pathophysiology and disease impact of EoE, new guidelines and appropriate treatments, and benefit strategies to improve timely treatment and quality of care for patients with EoE.
Educational Objectives
After completing this activity, the participant should be better able to:
Accreditation Information
 |
Joint Accreditation Statement |
Physician Continuing Medical Education
Partners designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Partners designates this continuing education activity for 1.5 contact hour (0.15 CEU) of the Accreditation Council for Pharmacy Education.
UAN: JA4008073-9999-26-085-H01-P
Activity Type: Application
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 ANCC contact hours.
Interprofessional Continuing Education
 |
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
DISCLOSURE OF CONFLICTS OF INTEREST
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
| Name of Faculty | Reported Financial Relationship |
|---|---|
| Evan S. Dellon, MD, MPH, faculty for this educational activity, has the following relevant financial relationships: | Consultant, Advisor, Speaker: Abbvie, Adare/Ellodi, Alfasigma, ALK, Allakos, Amgen, Anaptysbio, Apogee, Apollo, Aqilion, Arena/Pfizer, AstraZeneca, Bethanamist, Biocryst, Bryn, Calypso, Celgene/Receptos/BMS, Celldex, Cyted, Domain, EsoCap, Eupraxia, Dr. Falk Pharma, Ferring, GI Reviewers, GSK, Holoclara, Invea, Knightpoint, LucidDx, Nexstone Immunology/Uniquity, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Roivant, Sanofi, Shire/Takeda, Target RWE, Third Harmonic Bio, Upstream Bio Researcher: Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, Celldex, Dr. Falk Pharma, Eupraxia, Ferring, GSK, Meritage Educational grants: Allakos, Aqilion, Holoclara, Invea |
| Mary Jo Strobel, faculty for this educational activity, has the following relevant financial relationships: | Grants to institution: [Abbott, Ajinomoto Cambrooke, AstraZeneca, Bristol-Myers Squibb, Ellodi, EnteroTrack, Eupraxia, EvoEndo, GSK, Mead Johnson Nutrition, mBiota, Nutricia, Regeneron, PhRMA, Revolo, Sanofi, Takeda, Uniquity]. No personal compensation is received |
| Steven Kheloussi, PharmD, MBA, FAMCP, faculty for this educational activity, has no relevant financial relationships. | Nothing to disclose. |
| Bryan Buechel, PharmD, MBA, faculty for this educational activity, has the following relevant financial relationships: | Individual publicly traded stocks and stock options: Pfizer |
| Sal Morana, RPh, PhD, faculty for this educational activity, has no relevant financial relationships. | Nothing to disclose. |
| Hiva Pourarsalan, PharmD, faculty for this educational activity, has no relevant financial relationships. | Nothing to disclose. |
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
